News & Updates
Filter by Specialty:
Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
Use of pimavanserin appears to be more effective than atypical antipsychotic agents in reducing mortality among Parkinson’s disease patients during the first 180 days of treatment, reveals a study. However, such benefit is seen only in community-dwelling patients and not in nursing home residents.
Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
26 Aug 2022
Appeal to emotion, interpersonal relevance important in diabetes risk communication
Communicating the risks of type 2 diabetes needs to be done in an emotionally impactful way while also having an interpersonal appeal, according to a recent Singapore study. To improve the uptake of healthy lifestyle practices, shifting from a long-term view of the disease to more short-term, observable benefits may be valuable.
Appeal to emotion, interpersonal relevance important in diabetes risk communication
26 Aug 2022
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
25 Aug 2022
Use of antipsychotics, but not opioids, drops in nursing home residents with dementia
Prescription of antipsychotic and anxiolytic medications has decreased among residents with dementia in Veterans Health Administration (VHA) nursing homes, but overall prescribing of other psychotropic and opioid agents has increased, reports a study.
